Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Latest Information Update: 13 May 2020
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Pembrolizumab (Primary) ; Vinorelbine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 20 Apr 2020 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 20 Apr 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Aug 2021.
- 06 Nov 2019 Interim results released (n=18) at the 61st Annual Meeting and Exposition of the American Society of Hematology